Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Norris Comprehensive Cancer Center Millennium Pharmaceuticals, Inc. |
---|---|
Information provided by: | Norris Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT00183937 |
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.
PS 341 is a type of drug known as a “proteasome inhibitor.” By inhibiting the “proteasome” in cancer cells, PS-341 alters the way those cells divide). We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests (prostate specific antigen, also called PSA), and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: PS 341 Drug: Docetaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A PHASE II STUDY OF BORTEZOMIB (VELCADE®, PS-341) AND DOCETAXEL FOR PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
In determining eligibility the more abnormal of the two values (AST or ALT) should be used.
Exclusion Criteria:
Macrolide antibiotics: erythromycin, troleandomycin, azithromycin Imidazole antifungal agents: ketoconazole, itraconazole, fluconazole HIV protease inhibitors Immunosuppressive agents: cyclosporin, FK-506
United States, California | |
USC/Norris Comprehensive Cancer Center | |
Los Angeles, California, United States, 90033 |
Principal Investigator: | David Quinn, MD | University of Southern California |
Study ID Numbers: | 4P-04-3 |
Study First Received: | September 9, 2005 |
Last Updated: | May 5, 2006 |
ClinicalTrials.gov Identifier: | NCT00183937 |
Health Authority: | United States: Food and Drug Administration |
Docetaxel Prostatic Diseases Genital Neoplasms, Male Bortezomib |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |